VIDEO: Mark Zitter, MBA, Speaks About the Importance of Oncology Pathways

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.